Lead Indication
Syntherian spinal cord focuses on restoring functional neural connectivity following debilitating injury or loss of function.
By integrating engineered neural tissue with scalable, performance-validated manufacturing, we aim to enable measurable and durable circuit recovery for patients living with spinal cord injuries.
Building on published research from the Cullen Laboratory at the University of Pennsylvania, engineered neural tissues has shown to be capable of supporting organized axonal growth and signal transmission and continue to be developed and evaluated in preclinical models.
Ongoing work is focused on refining cellular composition, structural architecture, and host integration while establishing quantitative performance criteria necessary for therapeutic translation.
Scientific advancement of the spinal cord program proceeds in parallel with the development of Syntherian’s engineered tissue manufacturing platform. Validation of neural constructs must occur alongside the establishment of reproducible processes capable of generating standardized, clinically relevant tissues.
By aligning biological development with scalable manufacturing, Syntherian is working to ensure that advances in spinal cord repair translates into therapeutic constructs that can be consistently produced and ultimately delivered to patients.
